Search 

One Top Chinese Pharma

Focus on cancer,intestinal disease

As an investment and management platform established by UK-listed company Cathay International Holdings Limited, Lansen has built up pharmaceutical segment, health segemtn and cosmetic segment. Lansen has been listed in Stock Exchange of Hong Kong Limited (SEHK) on May 7, 2010. Lansen's top products are in rheumatology and dermatology area, and Lansen has established an extensive distribution network, with more than 300 frontline sales staff and more than 1500 distributors. By licensing in promising products at commercial stage and clinical stage, or other cooperation patterns, Lansen plans to expand to more diseases medication market, including rheumaotlogy, dermatology, orthopedics and nephrology.

Luoxin is an A share listed pharma with focus on Respiratory, GI, infectious disease as well as on oncology.

Investment banking boutique specialized in cross-border medical device transactions.
We would like to bring to your next events exclusive opportunities from Western companies in the fields of: robotics, cancer screening, liver disease diagnostic, robotics, cardiovascular and respiratory

Digital physician platform for over 2.5 million registered Chinese doctors. We also help US pharma, biotech and medical device companies strategize and promote products and services directly to Chinese physicians.

Nuance Biotech (Shanghai) Co. Ltd was founded in 2014.
Leading China based biotech company focussed on commercial, regulatory and development stage assets.
Nuance is directed by a world class board of directors and managed by an experienced China based management team with a strong track record. Backed a leading global tier 1 investor with more than USD 1 billion under management in China – Matrix Partners. The company strategy and approach allows for a highly scalable commercial and drug development model i.e. ability to run multiple initiatives.

Opera CRO is an international contract research organization (CRO) with offices in Italy (Genoa), in Switzerland (Geneva) and in Romania (Timisoara) that has been managing clinical trials since 1995. In particular, we performed several clinical studies with medical devices, medical drugs and food supplements in many different therapeutic areas.

We offer the possibility of conducting clinical trials in different countries in Eastern Europe, with reduced costs and faster times, or in other European and non-European countries (Italy, France, Switzerland, Germany etc..). Additionally, we offer specific support for the compliance of medical device registrations of the CE marking to the new European regulation. Recently, Opera CRO was acquired by the Tigermed group, the largest CRO in Asia with over 5000 employees and 100 offices. This partnership offers the opportunity to perform clinical trials in China and in the rest of Asia and access that vast market.
The list of our current studies can be found on ClinicalTrial.gov (specifying Opera CRO for Europe, Tigermed for Asia); further information is available on our website: www.operacro.com.